<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02745392</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2016-001</org_study_id>
    <nct_id>NCT02745392</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine</brief_title>
  <acronym>Zotrip</acronym>
  <official_title>Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zosano Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zosano Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multi-center, parallel-group study designed to compare
      the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle
      systems to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, multi-center, parallel group study designed to compare
      the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle
      systems to placebo. Subjects who have consented and meet the entry criteria will be
      randomized to one of four blinded treatment groups. There will be a screening period of up to
      1 week, followed by a run-in period to record migraine activity. The run-in period is to
      determine eligibility for randomization, and is planned to be 4 weeks in duration but may be
      extended up to an additional 4 weeks to accommodate scheduling. Qualified subjects will
      randomize to the double-blind treatment period at Day 0 and will have up to 8 weeks to
      confirm and treat a qualifying migraine. Using the eDiary to confirm they are experiencing a
      qualified migraine, subjects will self-administer the patch or patches and continue to
      respond to questions in the eDiary for 48 hours post treatment administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Pain Freedom</measure>
    <time_frame>2 hours</time_frame>
    <description>Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)</measure>
    <time_frame>2 hours</time_frame>
    <description>The proportion of subjects with freedom from the subject's pre-specified most bothersome symptom at 2 hours is one of two parts of the co-primary efficacy endpoint. This endpoint will be evaluated separately but both endpoints have to be met statistically for the study to be considered a success.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>ZP-Zolmitriptan 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZP-Zolmitriptan 1 mg patch single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZP-Zolmitriptan 1.9 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZP-Zolmitriptan 1.9 mg patch single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZP-Zolmitriptan 3.8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (either single or double patch) single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP-Zolmitriptan</intervention_name>
    <description>ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
    <arm_group_label>ZP-Zolmitriptan 1 mg</arm_group_label>
    <arm_group_label>ZP-Zolmitriptan 1.9 mg</arm_group_label>
    <arm_group_label>ZP-Zolmitriptan 3.8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 1 year history of episodic, acute migraine (with or without aura) with
             onset prior to 50 years of age. Diagnosis must comply with International Headache
             Society (IHS) diagnostic criteria. Diagnostic criteria must include a history of at
             least five attacks not attributed to any other disorder that include all of the
             following criteria:

               1. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)

               2. Headache has at least two of the following characteristics:

             (i) unilateral location (ii) pulsating quality (iii) moderate or severe pain intensity
             (iv) aggravation by or causing avoidance of routine physical activity (e.g., walking
             or climbing stairs) c) During headache at least one of the following: (i) nausea
             and/or vomiting (ii) both photophobia and phonophobia

          -  Migraine history during the 6-month period prior to the run-in period must include:
             2-8 migraines per month and no more than 10 headache days per month

          -  Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy
             during the trial, and must use an acceptable methods of birth control for the duration
             of the trial.

          -  No significant ECG findings, defined by:

               1. ischemic changes

               2. Q-waves in at least two contiguous leads,

               3. clinically significant intra-ventricular conduction abnormalities (left bundle
                  branch block or Wolf-Parkinson-White syndrome), or

               4. clinically significant arrhythmias (e.g., current atrial fibrillation)

          -  Able to understand the operation of the electronic diary and is able to apply the demo
             study drug patch.

        Exclusion Criteria:

          -  Contraindication to triptans

          -  Use of any prohibited concomitant medications within 10 days of the Run-in Period

          -  History of hemiplegic or basilar migraine

          -  Participation in another investigational trial during the 30 days prior to the Run-in
             Period or during this study

          -  Previous participation in a clinical trial of ZP-Zolmitriptan

          -  Diagnosis of cancer (other than non-invasive skin cancer) within the 5 years prior to
             the Run-in Period

          -  History of unstable psychiatric illness requiring medication or hospitalization in the
             12 months prior to the Run-in Period

          -  Subjects who have known allergy or sensitivity to zolmitriptan or its derivatives or
             formulations

          -  Subjects who have known allergy or sensitivity to adhesives

          -  Planned participation in activities which cause inflammation, irritation, sunburn,
             lesions, or tattoos at the intended application site from two weeks prior to screening
             through the last day of study participation

          -  Use of opiate analgesics or barbiturates more frequently than one day/week

          -  Women who are pregnant, breast-feeding or plan a pregnancy during this study

          -  Clinically significant liver disease

          -  Clinically significant kidney disease

          -  History of coronary artery disease (CAD), coronary vasospasm (including Prinzmetal's
             angina), aortic aneurysm, peripheral vascular disease or other ischemic diseases
             (e.g., ischemic bowel syndrome or Raynaud's syndrome)

          -  Three or more of the following CAD risk factors:

               -  Current tobacco use

               -  Hypertension or receiving anti-hypertensive medication for treatment of
                  hypertension

               -  Hyperlipidemia or on prescribed anti-cholesterol treatment

               -  Family history of premature coronary artery disease (&lt; 55 years of age in male
                  first degree relatives or &lt; 65 years of age in female first degree relatives)

               -  Diabetes mellitus

          -  History of cerebral vascular accident, transient ischemic attacks, or seizures

          -  Hospitalization within the 30 days prior to the Run-in Period

          -  Any other household member currently participating in a ZP-Zolmitriptan study or
             relatives of site staff

          -  Any reason to believe that compliance with the study requirements and completion of
             evaluations required for this study will not be possible

          -  History or current abuse or dependence on alcohol or drugs that would interfere with
             adherence to study requirements

          -  Any clinically relevant abnormal findings in the physical exam, vital signs or
             laboratory tests that, in the opinion of the Investigator, may put the subject at risk

        To be eligible for Treatment, subjects must continue to meet all eligibility criteria and
        the following criteria observed during the Run-in Period:

          1. An average of at least two qualifying migraines per 28-day period

          2. No more than 10 headache days in the last 28 days prior to randomization

          3. Demonstrated ability to properly use the eDiary and apply the demo study drug patch

          4. Confirmation of continuing good general health, or stable non-serious disease that in
             the opinion of the Investigator will not place the subject at risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Kellerman, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>Zosano Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Thunderbird Internal Medicine</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Center of Southern California</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Specialists Medical Group and Research Center</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown LA Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Associates of Southern California</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Associates of Santa Clara Valley Research Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy &amp; AsthmaCenters, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ki Health Partners</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novex Medical Research</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Medical Research Associates, Inc.</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Head Pain &amp;Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center, P.C</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute, Inc.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest/A Division of Banyan Group Inc.</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Research Institute</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princeton Center for Clinical Research</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Wellness Center, PC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research LLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Neurosciences Group</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911-3568</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <results_first_submitted>January 19, 2018</results_first_submitted>
  <results_first_submitted_qc>January 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2018</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>migraine headache</keyword>
  <keyword>acute migraine</keyword>
  <keyword>acute migraine headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (either single or double patch) single administration
Placebo: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)</description>
        </group>
        <group group_id="P2">
          <title>ZP-Zolmitriptan 1 mg</title>
          <description>ZP-Zolmitriptan 1 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
        </group>
        <group group_id="P3">
          <title>ZP-Zolmitriptan 1.9 mg</title>
          <description>ZP-Zolmitriptan 1.9 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
        </group>
        <group group_id="P4">
          <title>ZP-Zolmitriptan 3.8 mg</title>
          <description>ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Either single or double patch administration</description>
        </group>
        <group group_id="B2">
          <title>ZP-Zolmitriptan 1 mg</title>
          <description>Single 1 mg patch administration</description>
        </group>
        <group group_id="B3">
          <title>ZP-Zolmitriptan 1.9 mg</title>
          <description>Single 1.9 mg patch administration</description>
        </group>
        <group group_id="B4">
          <title>ZP-Zolmitriptan 3.8 mg</title>
          <description>Double 1.9 mg patch administration</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="321"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="11.53"/>
                    <measurement group_id="B2" value="41.7" spread="11.58"/>
                    <measurement group_id="B3" value="40.1" spread="10.92"/>
                    <measurement group_id="B4" value="41.0" spread="11.39"/>
                    <measurement group_id="B5" value="41.3" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Pain Freedom</title>
        <description>Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours.</description>
        <time_frame>2 hours</time_frame>
        <population>mITT population includes all subjects who were randomized, received any amount of study drug (applied the patch(es) to treat a qualifying migraine, and had at least 1 post-treatment efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (either single or double patch) single administration
Placebo: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)</description>
          </group>
          <group group_id="O2">
            <title>ZP-Zolmitriptan 1 mg</title>
            <description>ZP-Zolmitriptan 1 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
          </group>
          <group group_id="O3">
            <title>ZP-Zolmitriptan 1.9 mg</title>
            <description>ZP-Zolmitriptan 1.9 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
          </group>
          <group group_id="O4">
            <title>ZP-Zolmitriptan 3.8 mg</title>
            <description>ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Pain Freedom</title>
          <description>Pain Freedom at 2 hours post study drug administration is one of the co-primary endpoints. Subjects were queried via their eDiary about their level of migraine pain (none, mild, moderate, or severe) at various intervals post-dose. Subjects who answered none at 2 hours post study drug were considered pain free at 2 hours.</description>
          <population>mITT population includes all subjects who were randomized, received any amount of study drug (applied the patch(es) to treat a qualifying migraine, and had at least 1 post-treatment efficacy assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)</title>
        <description>The proportion of subjects with freedom from the subject's pre-specified most bothersome symptom at 2 hours is one of two parts of the co-primary efficacy endpoint. This endpoint will be evaluated separately but both endpoints have to be met statistically for the study to be considered a success.</description>
        <time_frame>2 hours</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (either single or double patch) single administration
Placebo: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)</description>
          </group>
          <group group_id="O2">
            <title>ZP-Zolmitriptan 1 mg</title>
            <description>ZP-Zolmitriptan 1 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
          </group>
          <group group_id="O3">
            <title>ZP-Zolmitriptan 1.9 mg</title>
            <description>ZP-Zolmitriptan 1.9 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
          </group>
          <group group_id="O4">
            <title>ZP-Zolmitriptan 3.8 mg</title>
            <description>ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Freedom From Most Bothersome Pre-specified Other Symptom (Nausea, Photophobia, or Phonophobia Pre-specified by Subject)</title>
          <description>The proportion of subjects with freedom from the subject's pre-specified most bothersome symptom at 2 hours is one of two parts of the co-primary efficacy endpoint. This endpoint will be evaluated separately but both endpoints have to be met statistically for the study to be considered a success.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2-8 days post-study drug administration for a single migraine</time_frame>
      <desc>The number of subjects at risk includes only subjects who treated with study drug (333). Although 365 subjects were randomized, not all subjects had a migraine (a criterion for administering study drug) between randomization and the end of the trial. 32 subjects (8 in the placebo group, 10 in ZP-Zolmitriptan 1 mg, 5 in ZP-Zolmitriptan 1.9 mg, 9 in ZP-Zolmitriptan 3.8 mg) did not treat with study drug, and that is the difference between the number of subjects randomized and the number at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (either single or double patch) single administration
Placebo: Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)</description>
        </group>
        <group group_id="E2">
          <title>ZP-Zolmitriptan 1 mg</title>
          <description>ZP-Zolmitriptan 1 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
        </group>
        <group group_id="E3">
          <title>ZP-Zolmitriptan 1.9 mg</title>
          <description>ZP-Zolmitriptan 1.9 mg patch single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
        </group>
        <group group_id="E4">
          <title>ZP-Zolmitriptan 3.8 mg</title>
          <description>ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
ZP-Zolmitriptan: ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Application site bruise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Application site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Application site swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Donald Kellerman</name_or_title>
      <organization>Zosano Pharma Corporation</organization>
      <phone>(510) 745-4004</phone>
      <email>dkellerman@zosanopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

